Abstract Aim In 2005, the Japan Geriatrics Society published a list of potentially
inappropriate medication that was an extract from the “Guidelines for medical treatment and …

Heart failure (HF) is a leading cause of morbidity, hospitalization, and mortality in older
adults and a growing public health problem placing a huge financial burden on the health …

Appropriate interpretation of changes in markers of kidney function is essential during the
treatment of acute and chronic heart failure. Historically, kidney function was primarily …

Objectives: The study objective was to assess the association between angiotensin-
converting enzyme inhibitor (ACEI)/angiotensin receptor blocker (ARB) use and mortality in …

Aims In heart failure (HF) with reduced ejection fraction (EF), renin–angiotensin receptor
(RAS) antagonists reduce mortality. However, severe renal insufficiency was an exclusion …

As shown in Figure 2, there is a stepwise incremental age-standardized risk for all-cause
mortality, cardiovascular events, and hospitalization associated with diminishing renal …

Aims In heart failure with reduced ejection fraction (HFrEF), renin–angiotensin system
inhibitors (RASi) improve morbidity and mortality. However, patients aged> 80 years …

BACKGROUND: Angiotensin-converting enzyme inhibitors improve outcomes in systolic
heart failure (SHF). However, doubts linger about their effect in SHF patients with chronic …

Aims During the post‐discharge phase following a heart failure hospitalization (HFH),
patients are at high risk of early readmission despite standard of care therapy. We examined …

Aims Cardiovascular hospitalization (CVH) in patients with heart failure (HF) is associated
with a high post-discharge rate of early re-admission and CV death. Eplerenone might be …